Last update 21 Jun 2024

Zanamivir

Last update 21 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid, 4-guanidino Neu5Ac2en, 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid

+ [14]

Target

neuraminidase

Mechanism

neuraminidase inhibitors(Neuraminidase inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesNervous System Diseases+ [1]

Active Indication

Influenza A virus infectionInfluenza B virus infectionInfluenza, Human+ [1]

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline Trading Services Ltd.Laboratoire GlaxoSmithKline SAS

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (26 Jul 1999),

Influenza, Human

Regulation-

Structure

Molecular FormulaC12H20N4O7

InChIKeyARAIBEBZBOPLMB-UFGQHTETSA-N

CAS Registry139110-80-8

Clinical Trials associated with Zanamivir

NCT04597437 / RecruitingEarly Phase 1IIT

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Start Date15 Mar 2024

Sponsor / Collaborator

George Washington University

[+2]

NCT05648448 / RecruitingPhase 2IIT

ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other.
AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator

Start Date22 Feb 2023

Sponsor / Collaborator

University of Oxford

NCT04494412 / RecruitingPhase 2

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection

Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infection remains a medical unmet need. Given the immaturity of the immune system at this age, there are no licensed influenza vaccines for children aged less than six months old. As a requirement of the Pediatric Investigation Plan European Union (EU), GlaxoSmithKline (GSK) will be conducting this open-label, multi-center, single arm, post-marketing authorization study to evaluate the PK and collect safety and tolerability information of IV zanamivir in hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The total duration of study participation for each participant will be up to 24 days with a study treatment period up to 10 days and 14 days of post-treatment follow up. However, for a given participant, the initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests as assessed by the investigator warrant further treatment. DECTOVA is a trademark of GlaxoSmithKline group of companies.

Start Date21 Nov 2022

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Zanamivir

100 Translational Medicine associated with Zanamivir

100 Patents (Medical) associated with Zanamivir

1,355

Literatures (Medical) associated with Zanamivir

01 Mar 2024·Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2022–23 season: Comparison with the 2010–11 to 2019–20 seasons

Article

Author: Bando, Takuma ; Kawai, Naoki ; Tani, Naoki ; Goto, Takeyuki ; Chong, Yong ; Ikematsu, Hideyuki

To assess the extent of susceptibility to the four neuraminidase inhibitors (NAIs) approved in Japan of the epidemic viruses in the 2022-23 influenza season in Japan, we measured the 50 % inhibitory concentration (IC₅₀) of oseltamivir, zanamivir, peramivir, and laninamivir in influenza virus isolates from patients. Viral isolation was done with specimens obtained prior to and after treatment, and the type/subtype was determined by RT-PCR using type- and subtype-specific primers. The IC₅₀ was determined by a neuraminidase inhibition assay using a fluorescent substrate. Virus isolates, one A(H1N1)pdm09 and 74 A(H3N2), were measured in the 2022-23 season. The geometric mean IC₅₀s of the 74 A(H3N2) isolated prior to treatment were 0.78 nM, 0.66 nM, 2.08 nM, and 2.85 nM for oseltamivir, peramivir, zanamivir, and laninamivir, respectively, comparable to those of the previous ten studied seasons. No A(H3N2) with highly reduced sensitivity to any of the NAIs was found in the 2022-23 season prior to or after drug administration. These results indicate that the sensitivity to these four commonly used NAIs has been maintained, at least for A(H3N2), in the 2022-23 influenza season in Japan, after the 2020-21 and 2021-22 seasons when the prevalence of influenza was extremely low.

01 Feb 2024·Irish journal of medical science

Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19

Article

Author: Alomar, Taghrid S ; Rauf, Abdur ; Almasoud, Najla ; Zafar, Rehman ; Khattak, Humayoon ; Jan, Muhammad Saeed ; Waseem, Wajeeha

OBJECTIVE:

The COVID-19 pandemic has been recognized as severe acute respiratory syndrome, one of the worst and disastrous infectious diseases in human history. Until now, there is no cure to this contagious infection although some multinational pharmaceutical companies have synthesized the vaccines and injecting them into humans, but a drug treatment regimen is yet to come.

AIM:

Among the multiple areas of SARS-CoV-2 that can be targeted, protease protein has significant values due to its essential role in viral replication and life. The repurposing of FDA-approved drugs for the treatment of COVID-19 has been a critical strategy during the pandemic due to the urgency of effective therapies. The novelty in this work refers to the innovative use of existing drugs with greater safety, speed, cost-effectiveness, broad availability, and diversity in the mechanism of action that have been approved and developed for other medical conditions.

METHODS:

In this research work, we have engaged drug reprofiling or drug repurposing to recognize possible inhibitors of protease protein 6M03 in an instantaneous approach through computational docking studies.

RESULTS:

We screened 16 FDA-approved anti-viral drugs that were known for different viral infections to be tested against this contagious novel strain. Through these reprofiling studies, we come up with 5 drugs, namely, Delavirdine, Fosamprenavir, Imiquimod, Stavudine, and Zanamivir, showing excellent results with the negative binding energies in Kcal/mol as - 8.5, - 7.0, - 6.8, - 6.8, and - 6.6, respectively, in the best binding posture. In silico studies allowed us to demonstrate the potential role of these drugs against COVID-19.

CONCLUSION:

In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues and the influence of these pronouncing drugs over these sequences. The outcome of this research work provides researchers with a track record for carrying out further investigational procedures by applying docking simulations and in vitro and in vivo experimentation with these reprofile drugs so that a better drug can be formulated against coronavirus.

24 Jan 2024·ACS applied materials & interfaces

Heteromultivalent Ligand Display on Reversible Self-Assembled Monolayers (rSAMs): A Fluidic Platform for Tunable Influenza Virus Recognition

Article

Author: Sergeeva, Yulia ; Sellergren, Börje ; Yeung, Sing Yee

We report on the design of heteromultivalent influenza A virus (IAV) receptors based on reversible self-assembled monolayers (SAMs) featuring two distinct mobile ligands. The principal layer building blocks consist of α-(4-amidinophenoxy)alkanes decorated at the ω-position with sialic acid (SA) and the neuraminidase inhibitor Zanamivir (Zan), acting as two mobile ligands binding to the complementary receptors hemagglutinin (HA) and neuraminidase (NA) on the virus surface. From ternary amphiphile mixtures comprising these ligands, the amidines spontaneously self-assemble on top of carboxylic acid-terminated SAMs to form reversible mixed monolayers (rSAMs) that are easily tunable with respect to the ligand ratio. We show that this results in the ability to construct surfaces featuring a very strong affinity for the surface proteins and specific virus subtypes. Hence, an rSAM prepared from solutions containing 15% SA and 10% Zan showed an exceptionally high affinity and selectivity for the avian IAV H7N9 (K_d = 11 fM) that strongly exceeded the affinity for other subtypes (H3N2, H5N1, H1N1). Changing the SA/Zan ratio resulted in changes in the relative preference between the four tested subtypes, suggesting this to be a key parameter for rapid adjustments of both virus affinity and selectivity.

News (Medical) associated with Zanamivir

10 Jan 2023

·www.prnewswire.com

Influenza A Market to Witness Robust Expansion at a CAGR of 8.5% in the United States During the Study Period (2019-2032), Assesses DelveInsight

The influenza A market is expected to surge in the coming years as the emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action for the treatment of patients affected with influenza A infections. At a global level, some key players in the influenza A market are Sanofi, AstraZeneca, GSK, and others. LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- DelveInsight's Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Influenza A Market Report As per DelveInsight analysis, the influenza A market size in the US was approximately USD 3.6 billion in 2021 According to the assessment done by DelveInsight, the total vaccinated pool of influenza A in the United States was approximately 176 million in 2021 Leading influenza A companies such as Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Genentech, Roche, BioCryst Pharmaceuticals, Sanofi, AstraZeneca, Seqirus, GSK, and others are developing novel influenza A drugs that can be available in the influenza A market in the coming years The promising influenza A therapies/vaccines in the pipeline include CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1 , and others The increase in influenza A market size is a direct consequence of an increase in R&D activity, increasing prevalent population, and the expected commercial success of upcoming therapies. In September 2022, Cidara Therapeutics announced the initiation of its Phase IIa trial to evaluate the pre-exposure prophylactic activity of CD388 against the influenza virus In April 2021, Cidara Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza Discover which therapies are expected to grab the major influenza A market share @ Influenza A Market Report Influenza A Overview Influenza is an acute viral respiratory disease caused by respiratory tract infection with influenza viruses (seasonal influenza A and B viruses) that circulate worldwide. Unlike annual seasonal epidemics, sporadic pandemic outbreaks are caused by zoonotic influenza A virus strains. Symptoms of influenza virus infection range from mild upper respiratory disease characterized by fever, sore throat, runny nose, cough, headache, muscle pain, and fatigue to severe and, in some cases, lethal pneumonia caused by influenza virus or secondary bacterial infection of the lower respiratory tract. The clinical presentation and epidemiological likelihood of infection are used to make an influenza A diagnosis. Nonspecific influenza A symptoms, such as fever, chills, frank shaking, headaches, myalgia, malaise, and anorexia, predominate at first. These influenza A symptoms usually appear suddenly, and respiratory symptoms, such as a dry cough, sore or dry throat, nasal obstruction, and discharge, are also present. Influenza A Epidemiology Segmentation DelveInsight estimates that the total influenza A positive cases in the United States comprised approximately 42.5K cases in 2021 and are projected to increase during the study period. In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, and 35,156 cases in 2021. The influenza A market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Vaccinated Pool of Influenza A Influenza A Positive Cases Strain-specific Cases of Influenza A (2019–2022) Download the report to understand which factors are driving influenza A epidemiology trends @ Influenza A Epidemiological Insights Influenza A Treatment Market Early antiviral intervention can benefit public health by improving clinical outcomes for patients at high risk of influenza-related complications, as well as potentially saving patients and the healthcare system money. MedImmune introduced the first licensed live attenuated influenza virus vaccine (LAIV) in the United States in 2003. This vaccine is based on the influenza A/Ann Arbor/6/1960 backbones. LAIVs appear to be more effective than inactivated influenza virus preparations at inducing mucosal and broadly protective immune responses in infants and children. However, studies in the United States with LAIVs have revealed poor efficacy against influenza A H1N1 component1. Another breakthrough for influenza vaccines occurred in 2013 when the FDA approved FLUZONE QUADRIVALENT, a product made entirely of recombinant DNA technologies. Antiviral drugs, in conjunction with vaccines, are critical in preventing and treating influenza virus infection and disease. During a typical influenza season, antiviral drugs are primarily used to treat severely ill patients, particularly those with a compromised immune system. TAMIFLU, RELENZA, and RAPIVAB are approved therapies that work by mimicking sialic acid binding in the active site of NA on influenza A and B viruses. To know more about influenza A guidelines, visit @ Influenza A Treatment Options Influenza A Pipeline Therapies/Vaccines and Key Companies CD388: Cidara Therapeutics SAB-176: SAb Biotherapeutics M2SR: FluGen mRNA-1010: Moderna VIR-2482: Vir Biotechnology VXA-A1.1: Vaxart Learn more about the FDA-approved influenza A drugs @ Drugs for Influenza A Treatment Influenza A Market Dynamics The dynamics of the influenza A market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Moreover, the presence of a large number of manufacturers contributes to the influenza A market growth. Furthermore, key players are heavily investing in research activities to broaden the therapeutic application of treatment drugs, thereby expanding the scope and opportunities for the treatment, thereby boosting the influenza A market growth. However, certain factors act as barriers and affect the influenza A market growth. The inadequate epidemiological data availability of patient care reference centers is among the prominent factors hampering the growth of the influenza A market. Moreover, the global influenza A market is fragmented, owing to the presence of several major players. Furthermore, payers and insurance companies will attempt to limit the use of drugs with mediocre efficacy but high prices, thus leading to a dip in the growth of the influenza A market. Hence, all these factors mentioned above are likely to impede the influenza A market growth in the future. Scope of the Influenza A Market Report Therapeutic Assessment: Influenza A current marketed and emerging therapies Influenza A Market Dynamics: Influenza A market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Influenza A Market Access and Reimbursement Discover more about influenza A drugs in development @ Influenza A Clinical Trials Table of Contents Related Reports Influenza A Epidemiology Forecast Influenza A Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted influenza A epidemiology in the 7MM, i.e., the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Influenza A Infections Pipeline Influenza A Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A infections companies, including Janssen Research & Development, LLC, Immune Targeting Systems Ltd, Vir Biotechnology, Inc., Guangdong Raynovent Biotech Co., Ltd, Hualan Biological Bacterin Co. Ltd., Celltrion, among others. Influenza B Infections Pipeline Influenza B Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza B infections companies, including Leyden Labs, Nanjing Zenshine Pharmaceuticals, SAB Biotherapeutics, among others. Influenza Pipeline Influenza Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osiva, among others. Seasonal Influenza Market Seasonal Influenza Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key seasonal influenza companies, including SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., among others. Influenza A Virus H5N1 Subtype Pipeline Influenza A Virus H5N1 Subtype Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza A virus H5N1 subtype companies, including Protein Sciences, Altimmune, Vaxart, Greffex, Cocrystal Pharma, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

VaccineLicense out/inDrug ApprovalPhase 2

26 Aug 2021

·www.biospace.com

Influenza Treatment Market to Garner $1.22 Billion by 2026 at 4.5% CAGR

Expansion in rates of flu across the globe, expansion in medical services use around the world, and flood in R&D ventures for revelation of new medications have impelled the development of the worldwide influenza treatment market. Allied Market Research as of late distributed a report, named, "Influenza Treatment Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Global Opportunity Analysis and Industry Forecast, 2019–2026". As indicated by the report, the worldwide influenza treatment industry was fixed at $861.5 million of every 2018, and is projected to hit $1.22 billion by 2026, developing at a CAGR of 4.5% from 2019 to 2026. Significant drivers for the market development Expansion in rates of flu across the globe, ascend in medical services use around the world, and ascend in R&D ventures for revelation of new medications have helped the development of the worldwide influenza treatment market. Nonetheless, presence of substitutes for the treatment of flu hamper the market development. In actuality, high development potential in agricultural nations is relied upon to set out worthwhile open doors sooner rather than later. Request Sample Report at: Oseltamivir Phosphate section ruled the market In light of type, the oseltamivir phosphate fragment held the biggest offer in 2018, representing more than two-fifths of the worldwide influenza treatment market. Oseltamivir is suggested by CDC and the American Academy of Pediatrics (AAP) for early treatment of influenza in individuals of all ages, which prpells the development of the fragment. In any case, the baloxavir marboxil portion is projected to show the most noteworthy CAGR of 4.6% during the estimate time frame. Baloxavir marboxil drug is viable against strains of flu A that are impervious to oseltamivir. Along these lines, this settles on it a favored decision in treatment if flu, consequently boosting the development of the section. The retail drug store section to show CAGR through 2026 In light of dissemination channel, the retail drug store section is projected to enroll the most noteworthy CAGR of 4.7% during the gauge time frame. Moreover, a similar portion held the biggest offer in 2018, representing almost 50% of the worldwide influenza treatment market. This is inferable from the solid presence of retail drug stores all throughout the planet and accommodation offered by them. The exploration likewise dissects portions including medical clinic drug store and others. North America held the vast majority The market across North America held the biggest offer in 2018, adding to around 33% of the market. This is attributable to flood in commonness of flu contamination in the area. Nonetheless, the worldwide influenza treatment market across Asia-Pacific is assessed to depict the quickest CAGR of 5.6% during the gauge time frame. This is because of flood in the mindfulness towards early finding of the ailment for better therapy flood in the mindfulness towards early conclusion of the ailment for better treatment. Major market players AstraZeneca Plc BioCryst Pharmaceuticals, Inc. Daiichi Sankyo Company Limited F. Hoffmann-La Roche AG GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Teva Pharmaceutical Industries Limited We have also published few syndicated market studies in the other trending area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Trending Reports: Antihyperlipidemic Drugs Market: Global Opportunity Analysis and Industry Forecast, 2019–2026 Irritable Bowel Syndrome Treatment Market: Global Opportunity Analysis and Industry Forecast, 2019–2026 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com

28 Apr 2011

·www.biospace.com

Biota, Inc. Announces Relenza Royalty for March 2011 Quarter

MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) advises that it has received written notification from GlaxoSmithKline that Relenza sales were $14.1 million and indicative royalties were $1.0 million, for the three months ended 31 March 2011. The figures were calculated on an Australian dollar exchange rate of 1.5576 to the UK pound, although the actual payment will be calculated on exchange rates at 30 April 2011.

100 Deals associated with Zanamivir

External Link

KEGG	Wiki	ATC	Drug Bank
D00902	Zanamivir	J05AH01	DB00558

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza A virus infection	EU	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza A virus infection	IS	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza A virus infection	LI	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza A virus infection	NO	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza B virus infection	EU	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza B virus infection	IS	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza B virus infection	LI	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza B virus infection	NO	GlaxoSmithKline Trading Services Ltd.	26 Apr 2019
Influenza, Human	US	GSK Plc	26 Jul 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthralgia	Phase 2	NL	GSK Plc	21 Nov 2022
Arthralgia	Phase 2	PL	GSK Plc	21 Nov 2022
Arthralgia	Phase 2	ES	GSK Plc	21 Nov 2022
Arthralgia	Phase 2	GB	GSK Plc	21 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01527110 (115215, CTgov)	Phase 3	Influenza A virus infection	21	Zanamivir	twgrfzxnmo(civmytcuno) = wlizdparky pemsrjtbsd (szvrrtcbyf, xsptudlpko - odugasjifl) View more	-	22 Feb 2018
NCT01231620 (CTgov)	Phase 3	Influenza, Human	626	Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 300mg Twice Daily)	yrosbeszgb(kvnbxashka) = gvbeowmsgj ovbxkbcxwe (twiqjzsmsq, mthnqzkfjb - dvamxcffuu) View more	-	20 Nov 2017
				Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 600mg Twice Daily)	yrosbeszgb(kvnbxashka) = ldyedlvmdt ovbxkbcxwe (twiqjzsmsq, rrufeiwrme - ubiaffamja) View more
NCT01014988 (CTgov)	Phase 2	Influenza, Human	202	zanamivir (Cohort 6: Adults (18 Years and Older))	qvcfzfcdjx(qxxvxdfjqz) = nzcncnbgqc bktljzbwzg (hvaapqmnvw, lwywuhovhn - dcgmuvueke) View more	-	28 Mar 2017
				zanamivir (Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years))	qvcfzfcdjx(qxxvxdfjqz) = odhqdubtqr bktljzbwzg (hvaapqmnvw, qwowigzpki - kopyhntmsx) View more
NCT01527110 (115215, Pubmed \| Curr Opin Pulm Med) Manual	Phase 3	Influenza, Human	21	zanamivir	uinfudgeol(tkfairades) = uxizyjwjxc asnwnmjbfs (oisueavsjj ) View more	Positive	01 Jan 2015
NCT01014988 (Pubmed \| Am J Trop Med Hyg)	Phase 2	Influenza, Human	202	Intravenous Zanamivir 600 mg	ejhvobavww(lghwwsmvzm) = lxdksnmqxb mflbepftgk (jqvxolqndg ) View more	-	15 Feb 2014
NCT00799760 (Pubmed \| Clin Microbiol Infect)	Phase 3	Influenza A virus infection	541	Oseltamivir	smjmdjhglw(iwxckixgiv) = xlmjbqevtk gkjqsvthfk (eifrhjovlf )	-	01 Feb 2013
				Zanamivir	smjmdjhglw(iwxckixgiv) = kubgpiephf gkjqsvthfk (eifrhjovlf )
NCT00784784 (CTgov)	Phase 3	Influenza, Human	64	Fluviral (Influenza Vaccine)	ehkpcgblcf(itwyvznckj) = pdndwialjg dtpnlgtgly (dxcfuvtpxw, smbmjtjdal - aklzdwffvh) View more	-	02 Sep 2011
				Zanamivir (Antiviral Prophylaxis)	ehkpcgblcf(itwyvznckj) = rskvjoxacn dtpnlgtgly (dxcfuvtpxw, onqgugqhks - vmjokkbsmp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis